Skip to main content
. Author manuscript; available in PMC: 2018 May 4.
Published in final edited form as: Nat Immunol. 2015 Aug 31;16(10):1077–1084. doi: 10.1038/ni.3252

Figure 5. IL-9 production by Id3−/− CD4+ T cells is involved in anti-tumor immunity.

Figure 5

(a) Tumor growth was monitored over time of Rag1−/− mice transferred intravenously with TCR plus TGF-β1-treated CD4+ CD25− T cells from Id3−/− or Id3+/+ mice simultaneously injected with B16 melanoma cells subcutaneously on day 0. The mice were treated with anti-IL-9 or isotype control antibodies every three days from day 0. (b) Representative tumors in each group harvested at the end of experiments as in a. (c) Intracellular staining of Foxp3, IFN-γ, IL-17, and IL-4 in intratumor CD4+ T cells as in a. Error bars represent mean ± SEM (n=4, Id3+/++ CtrlAb and Id3+/++α-IL-9; n=5, Id3−/−+ CtrlAb and Id3−/−+α-IL-9). *p<0.05, **p<0.01 (Student’s t-test). Data are representative of three independent experiments.